SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has entered into a collaborative research and license agreement with The University of Texas MD Anderson Cancer Center to evaluate and develop methylation assays focused on lung cancer, using Nucleix’s highly sensitive EpiCheck® platform.